NASDAQ:ALLR Allarity Therapeutics (ALLR) Stock Price, News & Analysis → READ THIS – If You Missed Out On The AI Boom (From Banyan Hill Publishing) (Ad) Free ALLR Stock Alerts $1.37 +0.10 (+7.87%) (As of 05:44 PM ET) Add Compare Share Share Today's Range$1.15▼$1.4450-Day Range$1.27▼$8.5652-Week Range$1.15▼$372.00Volume646,625 shsAverage Volume406,658 shsMarket Capitalization$2.67 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Allarity Therapeutics alerts: Email Address Allarity Therapeutics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish24.95% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($28.60) to ($30.40) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.02 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Allarity Therapeutics. Previous Next 2.0 Short Interest Percentage of Shares Shorted24.95% of the float of Allarity Therapeutics has been sold short.Short Interest Ratio / Days to CoverAllarity Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Allarity Therapeutics has recently increased by 317.06%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAllarity Therapeutics does not currently pay a dividend.Dividend GrowthAllarity Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALLR. Previous Next 1.7 News and Social Media Coverage News SentimentAllarity Therapeutics has a news sentiment score of 0.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.35 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Allarity Therapeutics this week, compared to 1 article on an average week.Search Interest11 people have searched for ALLR on MarketBeat in the last 30 days. This is an increase of 1,000% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Allarity Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Allarity Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.01% of the stock of Allarity Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 11.53% of the stock of Allarity Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Allarity Therapeutics are expected to decrease in the coming year, from ($28.60) to ($30.40) per share. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About Allarity Therapeutics Stock (NASDAQ:ALLR)Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.Read More ALLR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALLR Stock News HeadlinesApril 29, 2024 | finanznachrichten.deAllarity Therapeutics, Inc.: Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price RequirementApril 29, 2024 | globenewswire.comAllarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price RequirementMay 1, 2024 | InvestorPlace (Ad)Have You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...April 26, 2024 | americanbankingnews.comAllarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Up 317.1% in AprilApril 17, 2024 | finanznachrichten.deAllarity Therapeutics, Inc.: Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)April 17, 2024 | finance.yahoo.comAllarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)April 17, 2024 | globenewswire.comAllarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)April 12, 2024 | investorplace.comWhy Is Allarity Therapeutics (ALLR) Stock Up 41% Today?May 1, 2024 | InvestorPlace (Ad)Have You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...April 4, 2024 | finanznachrichten.deAllarity Therapeutics, Inc.: Allarity Therapeutics Announces 1-for-20 Reverse Stock SplitApril 4, 2024 | msn.comAllarity Therapeutics to implement 1-for-20 reverse stock splitApril 4, 2024 | globenewswire.comAllarity Therapeutics Announces 1-for-20 Reverse Stock SplitMarch 27, 2024 | globenewswire.comAllarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian CancerMarch 25, 2024 | globenewswire.comAllarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)March 8, 2024 | finanznachrichten.deAllarity Therapeutics, Inc.: Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business UpdateMarch 8, 2024 | benzinga.comAllarity Therapeutics: Q4 Earnings InsightsMarch 8, 2024 | globenewswire.comAllarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business UpdateFebruary 28, 2024 | globenewswire.comAllarity Therapeutics to Present at Biomarkers 2024February 23, 2024 | benzinga.comAllarity Therapeutics Stock (NASDAQ:ALLR), Short Interest ReportFebruary 23, 2024 | benzinga.comAllarity Therapeutics Stock (NASDAQ:ALLR) Dividends: History, Yield and DatesFebruary 2, 2024 | bizjournals.comBoston biotech loses Novartis drug license agreement for nonpaymentFebruary 2, 2024 | msn.comAllarity Therapeutics’ Licensing Agreement with Novartis TerminatedDecember 12, 2023 | markets.businessinsider.comAllarity Therapeutics CEO James Cullem Steps DownDecember 12, 2023 | finance.yahoo.comAllarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive AdvisorDecember 7, 2023 | finance.yahoo.comALLR: Stenoparib Clinical UpdateDecember 6, 2023 | seekingalpha.comAllarity stock soars 60% premarket on ovarian cancer therapy resultsDecember 5, 2023 | investorplace.comWhy Is Allarity Therapeutics (ALLR) Stock Up 42% Today?See More Headlines Receive ALLR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allarity Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/01/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ALLR CUSIPN/A CIK1860657 Webwww.allarity.com Phone401-426-4664FaxN/AEmployees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,900,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-91.78% Debt Debt-to-Equity RatioN/A Current Ratio0.14 Quick Ratio0.14 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($18.62) per share Price / Book-0.07Miscellaneous Outstanding Shares1,950,000Free Float1,946,000Market Cap$2.67 million OptionableNot Optionable Beta0.25 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Thomas H. Jensen (Age 46)Founder, CEO, Senior VP of Investor Relations & Director Ms. Joan Y. Brown (Age 70)Chief Financial Officer Comp: $180kMr. Peter Buhl Jensen Adj Professor (Age 69)M.D., M.D., Ph.D., Ph.D., Co-Founder Comp: $546.08kDr. Steen Meier Knudsen Ph.D. (Age 63)Founder & Chief Scientific Officer Comp: $185.11kKey CompetitorsSonoma PharmaceuticalsNASDAQ:SNOAAltamira TherapeuticsNASDAQ:CYTOCohBarNASDAQ:CWBRSalarius PharmaceuticalsNASDAQ:SLRXMustang BioNASDAQ:MBIOView All Competitors ALLR Stock Analysis - Frequently Asked Questions How have ALLR shares performed in 2024? Allarity Therapeutics' stock was trading at $11.0220 on January 1st, 2024. Since then, ALLR stock has decreased by 87.6% and is now trading at $1.37. View the best growth stocks for 2024 here. Are investors shorting Allarity Therapeutics? Allarity Therapeutics saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 105,100 shares, an increase of 317.1% from the March 31st total of 25,200 shares. Based on an average daily volume of 497,100 shares, the short-interest ratio is currently 0.2 days. Approximately 25.0% of the company's stock are sold short. View Allarity Therapeutics' Short Interest. When is Allarity Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ALLR earnings forecast. When did Allarity Therapeutics' stock split? Shares of Allarity Therapeutics reverse split on Tuesday, April 9th 2024. The 1-20 reverse split was announced on Tuesday, April 9th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 9th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Allarity Therapeutics? Shares of ALLR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ALLR) was last updated on 5/1/2024 by MarketBeat.com Staff From Our Partners😱 This phenomenon is smashing regular market gainsMillPubDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyForget Nvidia. This is the future of AIPorter & CompanyBiden out June 13; Kamala won’t replace him?Paradigm PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing4 coins to be the “Next Bitcoin”True Market InsidersThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allarity Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
